# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN
- Date: 2026-04-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Kidney biopsy result and start of treatment. **S**

## History of present illness

Ms. O'Connor had an ultrasound-guided kidney biopsy five days ago without bleeding. It shows ISN/RPS class III (A) lupus nephritis: focal endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, with no crescents or thrombotic microangiopathy. She heard the result from Dr. Okonjo-Strand by telephone two days ago, as she had asked, and again in full today. A levonorgestrel intrauterine system was inserted yesterday. Her joints and rash are unchanged; she has taken hydroxychloroquine and losartan for a week. Today she has the first of three methylprednisolone infusions, starts mycophenolate, and learns to give herself belimumab. She asked how to keep her mornings for writing through treatment. **S**

| Element | Detail |
|---|---|
| Biopsy | Class III (A) lupus nephritis; activity 6 of 24, chronicity 1 of 12 |
| Contraception | Intrauterine system inserted yesterday |
| Today | Methylprednisolone 500 mg (first of three); mycophenolate; first belimumab injection |
| Bone | DXA today |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Fatigue; low-grade fevers in the evenings |
| Musculoskeletal | Positive | Hand and knee pain and swelling unchanged; no hip or groin pain |
| Integumentary | Positive | Facial rash unchanged |
| Genitourinary | Negative | No pain at the biopsy site; no blood clots in the urine |
| Psychiatric | Negative | Determined; sleeping adequately |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day **S**
- Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**
- Methylprednisolone 500 mg intravenous infusion once daily for three days **S**
- Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months **S**
- Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily **S**
- Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly **S**
- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/80 mmHg; pulse 84 bpm; respirations 14/min; temperature 37 °C; oxygen saturation 99% on room air; weight 59.8 kg; BMI 21.2 kg/m². All vital signs are synthetic.

Hemoglobin: 11.2 g/dL (low); White cell count: 3.6 10*3/uL (low); Lymphocytes: 0.9 10*3/uL (low); Platelets: 151 10*3/uL; ALT: 18 U/L; 25-hydroxyvitamin D: 26 ng/mL (low); Lumbar spine Z-score (DXA): -0.4; Femoral neck Z-score (DXA): -0.2. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 11.2 g/dL (low) at this visit **S**
- White cell count: 3.3 10*3/uL (low) at baseline, 3.6 10*3/uL (low) at this visit **S**
- Lymphocytes: 0.8 10*3/uL (low) at baseline, 0.9 10*3/uL (low) at this visit **S**
- Platelets: 138 10*3/uL (low) at baseline, 151 10*3/uL at this visit **S**
- ALT: 19 U/L at baseline, 18 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired, composed; temperature 37.0 °C |
| Back | Biopsy site clean and healing; no tenderness |
| Skin | Malar rash as before |
| Musculoskeletal | Synovitis of the hands and wrists as before; full painless hip movement |
| Cardiovascular | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Class III lupus nephritis** (M32.14). Active focal proliferative lupus nephritis with little chronic damage and normal kidney function, so the outlook with treatment is good. Treatment follows the current ACR lupus nephritis guideline: pulse glucocorticoids, then an oral taper, with two other immunosuppressive drugs. She chose mycophenolate with belimumab, given by her own weekly injection at home, rather than mycophenolate with voclosporin, which needs closer kidney and blood pressure monitoring. The goal is a protein-to-creatinine ratio below 0.5 g/g within a year. **S**
   - Methylprednisolone 500 mg intravenously today and the next two days.
   - Then prednisone 30 mg daily, reduced by 5 mg every two weeks to 10 mg, then to 5 mg or less by six months.
   - Mycophenolate 500 mg twice daily for a week, then 1000 mg twice daily; blood counts weekly for the first month, twice monthly for the next two, then monthly.
   - Belimumab 400 mg weekly for four doses, then 200 mg weekly, by self-injection; report low mood.
   - Pneumocystis prophylaxis discussed and not started, because the prednisone dose falls below 20 mg within six weeks and sulfonamides are avoided in lupus; reconsider if the dose stays high.
2. **Glucocorticoid treatment: bone and avascular necrosis** (Z79.52). DXA Z-scores -0.4 at the spine and -0.2 at the femoral neck are normal for age, and with no fracture her fracture risk is low, so no osteoporosis drug is needed; vitamin D is low at 26. High-dose glucocorticoids carry a risk of avascular necrosis of the hip. **S**
   - Vitamin D3 1000 units daily and calcium from food.
   - Report any new hip, groin, or knee pain at once; MRI of the hips if it occurs.
   - Prednisone taken in the morning; watch glucose, blood pressure, sleep, and mood.
3. **Contraception** (Z97.5). Intrauterine system in place; pregnancy test negative; she can start mycophenolate. **S**
   - Keep the intrauterine system throughout mycophenolate treatment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Kidney biopsy | Before treatment | Up to date | Class III (A); activity 6 of 24; chronicity 1 of 12 |
| Medication safety | Pulse methylprednisolone and oral taper plan | At the start of treatment | Completed today | 500 mg today and for two more days; written taper schedule given |
| Laboratory | Blood count and liver tests before mycophenolate | Before the first dose, then weekly for a month, twice monthly for two months, then monthly | Completed today | White cells 3.6, lymphocytes 0.9, hemoglobin 11.2, platelets 151; ALT 18 |
| Medication safety | Pregnancy test and contraception before mycophenolate | Before the first dose | Completed today | Pregnancy test negative; intrauterine system inserted yesterday |
| Medication safety | Belimumab start and injection teaching | At the start | Completed today | First 400 mg dose given under supervision; she injected herself; warned to report low mood |
| Imaging | Bone density (DXA) at the start of glucocorticoids | As soon as possible after starting | Completed today | Lumbar spine Z-score -0.4; femoral neck Z-score -0.2 |
| Laboratory | 25-hydroxyvitamin D | At the start of glucocorticoids | Completed today | 26 ng/mL; vitamin D3 started |
| Examination | Avascular necrosis symptoms | Every visit | Completed today | No hip, groin, or knee pain; full hip movement |
| Medication safety | Hydroxychloroquine baseline eye examination | Within the first year | Ordered | Ophthalmology booked in two months |
| Laboratory | Potassium and creatinine after starting losartan | 2 to 4 weeks after starting | Due | Losartan started a week ago; to be drawn with the blood counts in two weeks |
| Examination | Blood pressure | Every visit | Completed today | 128/80 mmHg on losartan |
| Laboratory | Urine protein-to-creatinine ratio, sediment, creatinine, anti-dsDNA, and complements | Every 3 months during active treatment | Due | At three months |
| Medication safety | Recombinant zoster vaccine dose 2 | 1 to 2 months after dose 1 | Due | At the three-month visit |
| Self-management | Writing life and treatment schedule | Every visit | Completed today | Infusions booked in the afternoons; injections at home |

## Goal progress

- Establish the diagnosis within two weeks and hear it directly, in plain words. Outcome by 2026-04-22: Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary. **S**
- Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months. In progress; target 2026-10-26. **S**
- Prednisone 5 mg a day or less by six months, with withdrawal considered later. In progress; target 2026-10-26. **S**
- Write at least four mornings a week through treatment. In progress; target 2026-12-31. **S**
- No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines. In progress; target 2026-12-31. **S**

## Medication changes

- Started: Methylprednisolone 500 mg intravenous infusion once daily for three days **S**
- Started: Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six months **S**
- Started: Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice daily **S**
- Started: Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weekly **S**
- Started: Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**

## Guideline basis

- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022), American College of Rheumatology
- BENLYSTA (belimumab): prescribing information (subcutaneous dosing for lupus nephritis) (2026), U.S. National Library of Medicine, DailyMed
- CELLCEPT (mycophenolate mofetil): prescribing information (blood count monitoring, embryofetal toxicity, contraception) (2026), U.S. National Library of Medicine, DailyMed

## Follow-up

- Methylprednisolone tomorrow and the day after. Rheumatology blood counts weekly. Ophthalmology in two months. Three-month review. **S**
- Next scheduled visit 2026-07-27: three-month response assessment for lupus nephritis and glucocorticoid taper. **S**
